APA (7th ed.) Citation

H, I., T, N., H, F., N, K., Y, N., S, M., . . . T, T. (2026). Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker. Targeted oncology. https://doi.org/10.1007/s11523-026-01226-z

Chicago Style (17th ed.) Citation

H, Ishihara, et al. "Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker." Targeted Oncology 2026. https://doi.org/10.1007/s11523-026-01226-z.

MLA (9th ed.) Citation

H, Ishihara, et al. "Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker." Targeted Oncology, 2026, https://doi.org/10.1007/s11523-026-01226-z.